jmy Antibody

What is JMY and what cellular functions does it regulate?

JMY is a p300-binding protein with dual action in cellular processes. In the nucleus, it enhances P53 transcription and plays an important role in the cellular response to DNA damage. In the cytoplasm, it promotes actin filament assembly, thereby inducing cell motility in vitro . This protein has a molecular weight of approximately 111 kDa and may function either as a tumor suppressor or as an oncogene depending on cellular context . JMY is part of a specific protein family and has been studied in cancer research contexts due to its relationship with p53 and potential roles in cell motility that may influence metastasis .

What types of JMY antibodies are commercially available for research?

Several types of JMY antibodies are currently available for research applications:

The monoclonal antibody HMY117 recognizes a synthetic peptide from the C-terminus of the protein sequence (identical for both isoforms 1 and 2) . The rabbit polyclonal antibody is produced against a synthesized peptide derived from human JMY (amino acid range: 931-980) .

What experimental validation methods should I use when working with JMY antibodies?

For rigorous validation of JMY antibodies, employ multiple complementary approaches:

• Knockout (KO) cell lines: These serve as the gold standard negative controls, particularly for Western blotting and immunofluorescence applications. Recent research has demonstrated that KO cell lines are superior to other types of controls for antibody validation .

• Positive controls: Use cell lines known to express JMY, such as MCF7 and HeLa cells .

• Multiple detection methods: Validate findings across multiple techniques (e.g., Western blot, immunohistochemistry, and immunofluorescence) to ensure consistency.

• Specificity testing: Verify that the antibody detects proteins of the expected molecular weight (~111 kDa for JMY) .

• Cross-reactivity assessment: If working with mouse models, ensure the antibody demonstrates specificity across species barriers if claiming multi-species reactivity .

What are the optimal conditions for using JMY antibodies in Western blot applications?

Optimizing Western blot protocols for JMY detection requires attention to several key parameters:

• Antibody dilution:

  • For monoclonal antibodies like HMY117, start with manufacturer recommendations

  • For polyclonal antibodies like Boster A05423, a dilution range of 1:500-1:2000 is recommended

• Sample preparation:

  • When investigating nuclear functions of JMY, implement nuclear/cytoplasmic fractionation protocols

  • Use appropriate lysis buffers that preserve protein integrity while effectively extracting JMY

• Controls:

  • Always include positive controls (MCF7 or HeLa cells)

  • Include negative controls such as knockdown or knockout samples where possible

• Detection:

  • Given JMY's molecular weight of 111 kDa, use appropriate percentage SDS-PAGE gels (typically 8-10%)

  • Ensure sufficient transfer time for complete transfer of high molecular weight proteins

• Signal verification:

  • Confirm signal is at the expected molecular weight (~111 kDa)

  • Validate specificity by comparing with siRNA knockdown or CRISPR knockout controls

How should I distinguish between nuclear and cytoplasmic JMY in immunostaining experiments?

To effectively distinguish between nuclear and cytoplasmic JMY localization:

• Subcellular fractionation: Perform biochemical separation of nuclear and cytoplasmic fractions before Western blotting to quantify JMY distribution between compartments.

• Co-staining approaches: In immunofluorescence experiments, co-stain with:

  • Nuclear markers (DAPI, lamin proteins)

  • Actin cytoskeleton markers (phalloidin)

  • DNA damage markers (γ-H2AX) when studying DNA damage responses

• Experimental manipulations:

  • Induce DNA damage using UV irradiation or genotoxic agents to promote nuclear accumulation of JMY

  • Use motility assays to correlate cytoplasmic JMY with actin-related functions

• High-resolution imaging: Employ confocal microscopy with Z-stack analysis to accurately determine subcellular localization.

• Quantitative analysis: Develop nuclear/cytoplasmic intensity ratio measurements for objective assessment of JMY localization shifts under different experimental conditions.

How can I investigate JMY's dual roles in tumor suppression versus oncogenic functions?

Investigating JMY's context-dependent roles requires sophisticated experimental approaches:

• Cell type-specific analysis:

  • Compare JMY functions across cancer cell lines from different tissue origins

  • Correlate JMY expression levels with cellular phenotypes (proliferation, migration, invasion)

• Interaction networks:

  • Examine JMY interactions with p53 pathway components using co-immunoprecipitation

  • Analyze associations with actin cytoskeleton regulators

  • Perform ChIP assays to identify p53-dependent transcriptional targets influenced by JMY

• Genetic manipulation strategies:

  • Establish inducible expression systems to precisely control JMY levels

  • Use domain-specific mutants to separate nuclear versus cytoplasmic functions

  • Employ CRISPR-Cas9 to generate JMY knockout models for rescue experiments

• In vivo models:

  • Develop tissue-specific JMY knockout or overexpression mouse models

  • Assess tumor development, progression, and metastatic potential

• Clinical correlation:

  • Analyze JMY expression in patient tumor samples using validated antibodies

  • Correlate expression patterns with clinical outcomes and other molecular markers

What are best practices for troubleshooting non-specific binding with JMY antibodies?

When encountering non-specific binding issues with JMY antibodies:

• Blocking optimization:

  • Test different blocking agents (BSA, non-fat milk, commercial blockers)

  • Extend blocking time to reduce background

• Antibody validation:

  • Confirm antibody specificity using knockout controls as these have been shown to be superior to other validation methods

  • Test multiple antibodies targeting different epitopes of JMY

  • Consider using recombinant antibodies which have shown better performance than traditional monoclonal and polyclonal antibodies

• Protocol modifications:

  • Increase washing duration and frequency

  • Optimize primary antibody concentration and incubation conditions

  • Use detergents appropriate for the application (Tween-20, Triton X-100)

• Signal enhancement strategies:

  • Consider signal amplification systems for low-abundance detection

  • Use highly sensitive detection reagents

• Alternative approaches:

  • Supplement antibody-based detection with orthogonal methods (mass spectrometry)

  • Consider epitope tagging of JMY in model systems where feasible

How should I interpret contradictory results from different JMY antibodies?

When faced with discrepancies between results obtained using different JMY antibodies:

• Epitope considerations:

  • Map the epitopes recognized by each antibody

  • Consider whether post-translational modifications might affect epitope recognition

  • Determine if antibodies recognize different JMY isoforms

• Validation stringency:

  • Assess how thoroughly each antibody has been validated

  • Prioritize results from antibodies validated with knockout controls

  • Consider using recombinant antibodies which show better performance in multiple assays

• Technical variables:

  • Evaluate differences in experimental protocols

  • Consider fixation methods, which can dramatically affect epitope accessibility

  • Assess buffer compositions and their effects on protein conformation

• Reporting standards:

  • Document all experimental conditions thoroughly

  • Include appropriate controls in publications

  • Cite antibodies using Research Resource Identifiers (RRIDs)

• Integrated approach:

  • Combine results from multiple antibodies and techniques

  • Prioritize findings that are consistent across different methodologies

  • Use functional assays to support antibody-based observations

What considerations are important when publishing research using JMY antibodies?

To ensure reproducibility and rigor in JMY antibody-based research:

• Complete antibody documentation:

  • Report catalog numbers, lot numbers, and sources

  • Describe validation methods employed

  • Document dilutions and incubation conditions

• Control experiments:

  • Include both positive and negative controls

  • Document the use of knockout or knockdown validation

  • Show full blots or images rather than cropped versions

• Method transparency:

  • Provide detailed protocols

  • Describe image acquisition and processing parameters

  • Explain quantification methods for image analysis

• Cross-validation:

  • Confirm key findings with multiple techniques

  • Use complementary approaches (e.g., mass spectrometry)

  • Validate with genetic approaches (siRNA, CRISPR)

• Data availability:

  • Consider sharing raw image data

  • Deposit protocols in repositories

  • Follow journal-specific guidelines for antibody reporting

How might new antibody technologies improve JMY research?

Emerging technologies offer promising approaches for advancing JMY research:

• Recombinant antibody formats:

  • Recombinant antibodies have demonstrated superior performance compared to traditional monoclonal and polyclonal antibodies across multiple assays

  • These offer improved batch-to-batch consistency and specificity

• Nanobodies and single-domain antibodies:

  • Smaller size enables access to restricted epitopes

  • Better penetration in tissue samples

  • Potential for live-cell imaging applications

• Antibody engineering:

  • Site-specific labeling for super-resolution microscopy

  • Bifunctional antibodies for specialized applications

  • Photoswitchable antibodies for dynamic imaging

• Alternative protein binders:

  • Aptamers, affimers, and other non-antibody scaffolds

  • CRISPR-based tagging strategies

  • Proximity-dependent labeling approaches

• Multiplexed detection systems:

  • Simultaneous detection of JMY with interaction partners

  • Spatial transcriptomics combined with protein detection

  • Single-cell analysis technologies

What key experimental controls should be implemented when studying JMY in disease models?

When investigating JMY in disease contexts, particularly cancer models:

• Genetic controls:

  • CRISPR knockout cell lines serve as essential negative controls

  • Rescue experiments with wild-type and mutant JMY constructs

  • Inducible expression systems for dose-dependent studies

• Tissue-specific considerations:

  • Include multiple relevant cell types

  • Control for tissue-specific JMY expression patterns

  • Account for microenvironmental factors

• Functional validation:

  • Correlate JMY localization with functional outcomes

  • Perform p53-dependent transcriptional assays

  • Measure actin dynamics in migration/invasion assays

• Patient-derived models:

  • Validate findings in patient-derived xenografts or organoids

  • Compare with clinical samples

  • Correlate with patient outcomes data

• Therapeutic relevance:

  • Test effects of treatments on JMY expression and localization

  • Evaluate JMY as a potential biomarker

  • Assess JMY pathway modulation as a therapeutic strategy